Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: A comparative analysis through time lapse video-microscopy technique

References

• Aman A, Piotrowski T Cell migration during morphogenesis. Dev Biol 2010; 341: 20-33; PMID:19914236; http://dx.doi.org/10.1016/j.ydbio.2009.11.014
   PubMed Web of Science ®Google Scholar
• Errington RJ, Chappell SC, Khan IA, Marquez N, Wiltshire M, Griesdoorn VD, Smith PJ. Time-lapse microscopy approaches to track cell cycle and lineage progression at the single-cell level. Curr Protoc Cytom 2013; Chapter 12:Unit12.4; PMID:23546776; http://dx.doi.org/10.1002/0471142956
   PubMedGoogle Scholar
• Nakasone ES, Askautrud HA, Egeblad M. Live imaging of drug responses in the tumor microenvironment in mouse models of breast cancer. J Vis Exp 2013; 24(73):e50088; PMID:23542634
   PubMedGoogle Scholar
• Klein J, Leupold S, Biegler I, Biedendieck R, Münch R, Jahn D. TLM-Tracker: software for cell segmentation, tracking and lineage analysis in time-lapse microscopy movies.Bioinformatics 2012; 28(17):2276-7; PMID:22772947; http://dx.doi.org/10.1093/bioinformatics/bts424
   PubMed Web of Science ®Google Scholar
• Huth J, Buchholz M, Kraus JM, Mølhave K, Gradinaru C, v Wichert G, Gress TM, Neumann H, Kestler HA. TimeLapseAnalyzer: multi-target analysis for live-cell imaging and time-lapse microscopy. Comput Methods Programs Biomed 2011; 104(2):227-34; PMID:21705106; http://dx.doi.org/10.1016/j.cmpb.2011.06.002
   PubMed Web of Science ®Google Scholar
• Hardarson T, Hanson C, Claesson M, Stenevi U. Time-lapse recordings of human corneal epithelial healing. Acta Ophthalmol Scand 2004; 82(2 Suppl):184-8; PMID:15043538; http://dx.doi.org/10.1111/j.1600-0420.2004.00250.x
   PubMedGoogle Scholar
• Perfetto B, Stellavato A, Melito A, De Gregorio V, Cammarota M, Giuliano M. A time-lapse approach to examine chromium and nickel effects on wound healing in vitro. J Immunotoxicol 2012; 9 (4 Suppl): 392-400; PMID:22632163; http://dx.doi.org/10.3109/1547691X.2012.682662
   PubMed Web of Science ®Google Scholar
• Baum CL, Arpey CJ. Normal cutaneous wound healing: clinical correlation with cellular and molecular events. Dermatol Surg 2005; 31:674-86; PMID:15996419; http://dx.doi.org/10.1097/00042728-200506000-00011
   PubMed Web of Science ®Google Scholar
• Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR, et al. Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 2003; 88(12):1971-8; PMID:12799645; http://dx.doi.org/10.1038/sj.bjc.6600986
   PubMed Web of Science ®Google Scholar
• Caraglia M, D'Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004; 23(41):6900-13; PMID:15286715; http://dx.doi.org/10.1038/sj.onc.1207814
   PubMed Web of Science ®Google Scholar
• Caraglia M, Marra M, Naviglio S, Botti G, Addeo R, Abbruzzese A. Zoledronic acid: an unending tale for an antiresorptive agent. Expert Opin Pharmacother 2010; 11(1):141-54. Review; PMID:20001436
   PubMed Web of Science ®Google Scholar
• Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. Int J Pharm 2011; 403(1-2):292-7; PMID:21055454; http://dx.doi.org/10.1016/j.ijpharm.2010.10.046
   PubMed Web of Science ®Google Scholar
• Marra M, Salzano G, Leonetti C, Porru M, Franco R, Zappavigna S, Liguori G, Botti G, Chieffi P, Lamberti M, et al. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study. Biotechnol Adv 2012; 30(1):302-9. Epub 2011 Jun 30; PMID:21741464; http://dx.doi.org/10.1016/j.biotechadv.2011.06.018
   PubMed Web of Science ®Google Scholar
• Marra M, Salzano G, Leonetti C, Tassone P, Scarsella M, Zappavigna S, Calimeri T, Franco R, Liguori G, Cigliana G, et al. Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. Nanomedicine 2011; 7(6):955-64. Epub 2011 Mar 29; PMID:21453789
   PubMed Web of Science ®Google Scholar
• Aparicio A, Gardner A, Tu Y, Savage A, Berenson J, Lichtenstein A. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 1998; 12:220-9; PMID:9519785; http://dx.doi.org/10.1038/sj.leu.2400892
   PubMed Web of Science ®Google Scholar
• Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82:1459-68; PMID:10780527; http://dx.doi.org/10.1054/bjoc.1999.1131
   PubMed Web of Science ®Google Scholar
• Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 2001; 61:2602-8; PMID:11289137
   PubMed Web of Science ®Google Scholar
• Schafer WR, Rine J. Protein prenylation: genes, enzymes, targets, and functions. Annu Rev Genet 1992; 26:209-37; PMID:1482112; http://dx.doi.org/10.1146/annurev.ge.26.120192.001233
   PubMed Web of Science ®Google Scholar
• Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G, Budillon A. Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 2006; 13:7-26; PMID:16601276; http://dx.doi.org/10.1677/erc.1.01094
   PubMed Web of Science ®Google Scholar
• Caraglia M, D′Alessandro AM, Marra M, Giuberti G, Vitale G, Viscomi C, Colao A, Prete SD, Tagliaferri P, Tassone P, et al. The farnesyl transferase inhibitor R115777 (Zarnestra) synergistically enhances growth inhibition and apoptosis induced on epidermoid cancer cells by Zoledronic acid (Zometa) and Pamidronate. Oncogene 2004; 23:6900-13; PMID:15286715
   PubMed Web of Science ®Google Scholar
• Chen T, Berenson J, Vescio R, Swift R, Glichick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002; 42:1228-36; PMID:12412821; http://dx.doi.org/10.1177/009127002762491316
   PubMed Web of Science ®Google Scholar
• Skerjanec A, Berenson J, Hsu C, Major P, Miller WH Jr, Ravera C, Schran H, Seaman J, Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003; 43:154162; PMID:12616668; http://dx.doi.org/10.1177/0091270002239824
   PubMed Web of Science ®Google Scholar